Paper19756352
Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.
Maekawa S and 1 other. J Gastroenterol, 2009. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. Papers, record 19756352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19756352
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepacivirus | Major topic |
| Hepatitis C, Chronic | Major topic |
| Interferon-alpha | Major topic |
| Ribavirin | Major topic |
| Drug Therapy, Combination | |
| Genetic Variation | |
| Genotype | |
| Humans | |
| Interferon alpha-2 | |
| Polyethylene Glycols | |
| Recombinant Proteins | |
| Treatment Outcome | |
| Viral Load | |
| Virulence Factors |
Source PubMed
References83
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9143277 | Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. | Virology | 1997 | https://conductscience.org/library/papers/9143277 | PubMed |
| 2 | 18069766 | Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C. | World J Gastroenterol | 2007 | https://conductscience.org/library/papers/18069766 | PubMed |
| 3 | 1325713 | Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. | Virology | 1992 | https://conductscience.org/library/papers/1325713 | PubMed |
| 4 | 15888797 | Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. | Gut | 2005 | https://conductscience.org/library/papers/15888797 | PubMed |
| 5 | 17446688 | Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. | Microbiol Immunol | 2007 | https://conductscience.org/library/papers/17446688 | PubMed |
| 6 | 16958669 | Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. | J Gastroenterol Hepatol | 2006 | https://conductscience.org/library/papers/16958669 | PubMed |
| 7 | 16024941 | Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. | Intervirology | 2005 | https://conductscience.org/library/papers/16024941 | PubMed |
| 8 | 10669323 | Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. | J Infect Dis | 2000 | https://conductscience.org/library/papers/10669323 | PubMed |
| 9 | 14748063 | Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus. | J Med Virol | 2004 | https://conductscience.org/library/papers/14748063 | PubMed |
| 10 | 10406177 | Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. | J Hepatol | 1999 | https://conductscience.org/library/papers/10406177 | PubMed |
| 11 | 9334922 | Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. | J Med Virol | 1997 | https://conductscience.org/library/papers/9334922 | PubMed |
| 12 | 16279899 | Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. | Am J Gastroenterol | 2005 | https://conductscience.org/library/papers/16279899 | PubMed |
| 13 | 11773402 | Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. | J Virol | 2002 | https://conductscience.org/library/papers/11773402 | PubMed |
| 14 | 18448540 | Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. | J Virol | 2008 | https://conductscience.org/library/papers/18448540 | PubMed |
| 15 | 17973647 | Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. | Aliment Pharmacol Ther | 2008 | https://conductscience.org/library/papers/17973647 | PubMed |
| 16 | 16098627 | Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. | J Hepatol | 2005 | https://conductscience.org/library/papers/16098627 | PubMed |
| 17 | 17040112 | Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. | Drugs | 2006 | https://conductscience.org/library/papers/17040112 | PubMed |
| 18 | 9634077 | Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. | J Gen Virol | 1998 | https://conductscience.org/library/papers/9634077 | PubMed |
| 19 | 9247477 | Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. | Gastroenterology | 1997 | https://conductscience.org/library/papers/9247477 | PubMed |
| 20 | 19235866 | Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. | J Med Virol | 2009 | https://conductscience.org/library/papers/19235866 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31534084 | Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects. | Intern Med | 2020 | https://conductscience.org/library/papers/31534084 | PubMed |
| 25780333 | A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data. | Evol Bioinform Online | 2015 | https://conductscience.org/library/papers/25780333 | PubMed |
| 25578520 | Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. | Cytokine Growth Factor Rev | 2015 | https://conductscience.org/library/papers/25578520 | PubMed |
| 24708767 | Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy. | J Transl Med | 2014 | https://conductscience.org/library/papers/24708767 | PubMed |
| 23429668 | Clinical impact of hepatitis B and C virus envelope glycoproteins. | World J Gastroenterol | 2013 | https://conductscience.org/library/papers/23429668 | PubMed |
| 23314745 | Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. | Eur J Clin Microbiol Infect Dis | 2013 | https://conductscience.org/library/papers/23314745 | PubMed |
| 23193392 | Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2. | Gastroenterol Res Pract | 2012 | https://conductscience.org/library/papers/23193392 | PubMed |
| 23181537 | Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. | BMC Infect Dis | 2012 | https://conductscience.org/library/papers/23181537 | PubMed |
| 22993188 | NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. | J Clin Microbiol | 2012 | https://conductscience.org/library/papers/22993188 | PubMed |
| 21484111 | Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C. | Hepatol Int | 2013 | https://conductscience.org/library/papers/21484111 | PubMed |
| 20927636 | High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. | J Gastroenterol | 2011 | https://conductscience.org/library/papers/20927636 | PubMed |
| 20805953 | Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention. | Case Rep Gastroenterol | 2010 | https://conductscience.org/library/papers/20805953 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19756352
GET https://conductscience.org/api/papers/v1/19756352/references?page=2